Drug intelligence / Profile preview

zuberitamab

Development stage: Unknown
Lead developer: BioRay
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Zuberitamab is a novel, human-mouse chimeric monoclonal antibody targeting the CD20 antigen on B-cells. It is engineered to have enhanced antibody-dependent cellular cytotoxicity (ADCC) compared to first-generation CD20 antibodies like rituximab. Developed by Hansoh Pharma and studied extensively by institutions like Tianjin Medical University Cancer Institute and Hospital, it is currently being evaluated in combination therapies for B-cell malignancies. In the TRIUM trial, it is combined with zanubrutinib and sonrotoclax as a chemotherapy-free induction regimen for patients with previously untreated mantle cell lymphoma.

Other names: CD20mabCD-20mabCD 20mabzuberitamab

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on zuberitamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zuberitamab.

Explore the full profile